ADDITION OF BISMUTH TO THE STANDARD TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION
Status:
Completed
Trial end date:
2019-05-15
Target enrollment:
Participant gender:
Summary
H pylori is an important cause of chronic gastritis and other complications. There is a
decline in eradication rate for H pylori owing to multiple factors including drug resistance.
We compare the effect of the addition of bismuth to the standard triple therapy in a
randomized control trial.
Subjects were randomized into two arms. Arm A received triple therapy including amoxicillin,
clarithromycin, and omeprazole and Arm B received quadruple therapy adding colloidal bismuth
subcitrate. Both arms received treatment for two weeks.